Total Payments
$118,454
2024 Payments
$22,614
Companies
13
Transactions
93
Medicare Patients
1,607
Medicare Billing
$383,389
Payment Breakdown by Category
Other$100,446 (84.8%)
Consulting$13,347 (11.3%)
Food & Beverage$2,851 (2.4%)
Travel$1,754 (1.5%)
Education$56.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $100,446 | 39 | 84.8% |
| Consulting Fee | $13,347 | 4 | 11.3% |
| Food and Beverage | $2,851 | 37 | 2.4% |
| Travel and Lodging | $1,754 | 9 | 1.5% |
| Education | $56.36 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $63,462 | 36 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $28,357 | 19 | $0 (2024) |
| Celgene Corporation | $16,616 | 14 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $5,888 | 3 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,220 | 4 | $0 (2022) |
| National Marrow Donor Program | $370.87 | 2 | $0 (2024) |
| PFIZER INC. | $169.38 | 8 | $0 (2024) |
| Akcea Therapeutics, Inc. | $121.60 | 1 | $0 (2019) |
| Adaptive Biotechnologies Corporation | $106.66 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $96.34 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,614 | 22 | GENZYME CORPORATION ($19,945) |
| 2023 | $38,305 | 25 | GENZYME CORPORATION ($22,557) |
| 2022 | $29,523 | 17 | GENZYME CORPORATION ($15,008) |
| 2021 | $10,426 | 8 | Celgene Corporation ($4,658) |
| 2020 | $5,938 | 7 | Celgene Corporation ($3,703) |
| 2019 | $8,462 | 9 | Celgene Corporation ($8,255) |
| 2018 | $3,187 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($3,165) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,283.00 | General |
| 11/25/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,373.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $122.08 | General |
| 10/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $107.87 | General |
| Category: Oncology | ||||||
| 10/09/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Oncology | ||||||
| 10/08/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Oncology | ||||||
| 09/23/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $8.83 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $659.00 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO | Food and Beverage | In-kind items and services | $4.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/06/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO | Food and Beverage | In-kind items and services | $6.02 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/16/2024 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 04/28/2024 | National Marrow Donor Program | — | Food and Beverage | In-kind items and services | $214.51 | General |
| 04/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 04/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $104.09 | General |
| Category: Oncology | ||||||
| 03/07/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Oncology | ||||||
| 02/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $62.40 | General |
| Category: Oncology | ||||||
| 02/23/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Oncology | ||||||
| 02/07/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Oncology | ||||||
| 01/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $105.01 | General |
| Category: Oncology | ||||||
| 01/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $38.29 | General |
| Category: Oncology | ||||||
| 12/09/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $72.82 | General |
| Category: Oncology | ||||||
| 12/08/2023 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $104.09 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $9.22 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 466 | 967 | $466,256 | $93,674 |
| 2022 | 10 | 477 | 917 | $383,574 | $78,393 |
| 2021 | 8 | 344 | 1,117 | $489,370 | $113,174 |
| 2020 | 11 | 320 | 1,029 | $308,621 | $98,148 |
Total Patients
1,607
Total Services
4,030
Medicare Billing
$383,389
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 126 | 328 | $199,789 | $36,641 | 18.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 179 | $53,983 | $17,575 | 32.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 107 | $65,201 | $12,003 | 18.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 87 | 122 | $50,983 | $8,644 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 83 | 117 | $48,903 | $7,849 | 16.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 29 | $17,344 | $4,201 | 24.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 23 | 33 | $9,570 | $3,161 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $9,135 | $1,716 | 18.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 19 | 19 | $5,390 | $974.44 | 18.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 21 | $5,958 | $909.72 | 15.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 94 | 267 | $162,069 | $31,555 | 19.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 166 | $43,326 | $14,248 | 32.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 106 | $64,342 | $11,574 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 56 | 82 | $34,112 | $5,841 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 56 | 75 | $31,200 | $5,821 | 18.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 18 | 21 | $6,090 | $1,845 | 30.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 31 | $8,742 | $1,501 | 17.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $6,768 | $1,384 | 20.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $7,896 | $1,372 | 17.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 20 | 21 | $5,922 | $1,083 | 18.3% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 13 | 15 | $4,680 | $954.88 | 20.4% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Facility | 2022 | 34 | 46 | $3,726 | $565.26 | 15.2% |
| 84165 | Protein measurement, serum | Facility | 2022 | 34 | 46 | $3,726 | $559.26 | 15.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Facility | 2022 | 15 | 15 | $975.00 | $89.90 | 9.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 57 | 347 | $209,353 | $42,990 | 20.5% |
About Patrick Hagen, M.D., M.P.H
Patrick Hagen, M.D., M.P.H is a Hematology & Oncology healthcare provider based in Maywood, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2011. The National Provider Identifier (NPI) number assigned to this provider is 1265725592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Patrick Hagen, M.D., M.P.H has received a total of $118,454 in payments from pharmaceutical and medical device companies, with $22,614 received in 2024. These payments were reported across 93 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($100,446).
As a Medicare-enrolled provider, Hagen has provided services to 1,607 Medicare beneficiaries, totaling 4,030 services with total Medicare billing of $383,389. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Maywood, IL
- Active Since 05/19/2011
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1265725592
Products in Payments
- SARCLISA (Biological) $56,719
- Pomalyst (Drug) $17,772
- Revlimid (Drug) $11,958
- MOZOBIL (Drug) $6,946
- NINLARO (Drug) $3,220
- TEGSEDI (Drug) $121.60
- ELREXFIO (Drug) $112.92
- clonoSEQ (Device) $106.66
- KYMRIAH (Biological) $96.34
- BOSULIF (Drug) $45.56
- PREVYMIS (Drug) $19.81
- XPOVIO (Drug) $12.45
- BESPONSA (Biological) $10.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Maywood
Mohamad Khair Khasawneh, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Stephanie Tsai, M.d, M.D
Hematology & Oncology — Payments: $141,544
Hematology & Oncology $141,544
Agne Paner, M.d, M.D
Hematology & Oncology — Payments: $131,263
Hematology & Oncology $131,263
Joseph Clark, Md, MD
Hematology & Oncology — Payments: $102,053
Hematology & Oncology $102,053
Scott Smith, Md Phd, MD PHD
Hematology & Oncology — Payments: $101,319
Hematology & Oncology $101,319
Patrick Stiff, Md, MD
Hematology & Oncology — Payments: $28,293
Hematology & Oncology $28,293